ChinaBio® Today Blog | Talkmarkets | Page 1
News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

All Contributions

Latest Posts
1 to 16 of 259 Posts
1 2 3 ... 17
Week In Review: Bio-Thera Raises $241 Million In Shanghai STAR IPO For Antibody Portfolio
Bio-Thera Solutions of Guangzhou priced its IPO on Shanghai’s STAR Board to raise $241 million at a valuation of almost $2 billion. The offering, which placed 60 million shares at RMB32.76 each, was reported to be 3,225 times oversubscribed.
Week In Review: AkesoBio Files For $300 Million Hong Kong IPO
AkesoBio, a Zhongshan novel drug discovery and development biopharma, filed for a $300 million Hong Kong IPO to develop its portfolio of novel mono- and bi-specific antibodies.
Week In Review: Sorrento Therapeutics Fights $933 Million Take-Private Bid
Sorrento Therapeutics, a San Diego-Nanjing-Suzhou biopharma, rejected a $7 per share take-private offer from an unnamed PE company that valued the company at $933 million. Sorrento reported a loss of $57 million over the last 12 months.
Week In Review: South Korea's Celltrion Plans $513 Million Biologics Facility In Wuhan
Celltrion, a South Korea biopharma, plans to build a $513 million China biologics manufacturing facility in Wuhan. The company said the plant's 120,000 liter capacity will make it the largest facility in China.
Week In Review: China's I-Mab Stages $104 Million Nasdaq IPO
I-Mab, a Shanghai biotech, raised $104 million in its IPO on the Nasdaq exchange to support its portfolio of biologic products.The offering was priced at $14 per ADS but the price has moved 10% lower to $12.58 in initial trading.
Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020
Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia. Apollomics will be responsible for developing uproleselan and GMI-1687.
Week In Review: Shanghai's I-Mab Plans $100 Million NASDAQ IPO On January 16
I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the NASDAQ exchange at a market value of $750 million. The company plans to offer 7.4 million shares between $12 and $15.
Week In Review: Geneseeq And Elpiscience Close $100 Million VC Rounds; Zai Lab's PARP Inhibitor Approved For China Use
Geneseeq, a Nanjing-Toronto company offering genetic sequencing tests for cancer, completed a $114 million Series D financing led by China Reform Holdings Corporation. Geneseeq uses next-gen sequencing to provide decision-making tools for doctors.
Week In Review: Ally Bridge Leads $140 Million Of Investments In Three Medical Device Companies
Ally Bridge Group, a Hong Kong-New York life science investment firm, announced it has led $140 million of investments in three new medical device companies, bringing its 18-month total to more than $500 million in private life science companies.
Week In Review: AlphaMab Raises $234 Million In Hong Kong IPO; Climbs 35% In First Trading Session
Alphamab Oncology raised $234 million in a Hong Kong IPO and traded 35% higher from its offering price to a market cap of $1.2 billion. The company has a PD-L1 candidate that could be approved in China in 2020 and two bispecifics in Phase II tests.
Week In Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
Alphamab Oncology, a company developing eight bispecifics for oncology, plans to stage an IPO before the end of the year on the Hong Kong Exchange that could raise up to $350 million.
Week In Review: Pharmaron, A Beijing CRO, Stages $434 Million Hong Kong IPO
Pharmaron Beijing staged a $434 million Hong Kong IPO to expand its international CRO operations. In January, Pharmaron completed a $76 million IPO on the Shenzhen Exchange, and its stock price has quadrupled since its debut.
Week In Review: Fosun Pharma Acquires Brain Cancer Immunotherapy In $148 Million Deal
Shanghai Fosun Pharma announced a $148 million agreement to acquire China rights for SurVaxM, a novel immunotherapy aimed at glioblastoma, from MimiVax of Buffalo, New York.
Week In Review: BeiGene's BTK Inhibitor Approved In US And China Approval For PD-1 Expected In Two Months
Beijing's BeiGene had an outstanding week: its BTK drug, Brukinsa™, was approved for US use to treat mantle cell lymphoma, and its PD-1 candidate is poised for China approval before the end of the year to treat classical Hodgkin’s lymphoma.
Week In Review: AstraZeneca Announces $1 Billion Fund For China Life Science Startups
Deals, financings, trials and approvals in China biotech this past week.
Week In Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration With Amgen
BeiGene, a Beijing cancer biopharma, announced a blockbuster collaboration with Amgen. I-Mab, a Shanghai biopharma, has filed to IPO; Aesthetic Medical International Holdings, a Shenzhen aesthetics company, completed a $30 million IPO on NASDAQ.
1 to 16 of 259 Posts
1 2 3 ... 17